IDIOPATHIC PULMONARY FIBROSIS (ipf)
sndx-6352-0506
ELIGIBILITY & REQUIREMENTS
- Aged 40 or older
- Confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
WHAT'S INVOLVED
- The trial will run for approximately 44 weeks
- Eleven clinic visits to the Institute for Respiratory Health at QEII Medical Centre, Nedlands
- A health check by our doctors and nurses
- Reimbursement for travel expenses
STUDY OUTLINE
This research study will test Axatilimab solution for intravenous infusion, an investigational drug.
Axatilimab is a humanized IgG4 monoclonal antibody with high affinity against the colony-stimulating factor 1 receptor (CSF-1R). Recent experiments have demonstrated that use of an anti-CSF-1R antibody blocks fibrosis in fibrotic disease models.
In this research study, you will get either intravenous Axatilimab or placebo, which you will take in addition to your usual IPF medications.
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 0419 011 766 or (08) 6151 0888 or email clinicaltrials@resphealth.uwa.edu.au
PRINCIPAL INVESTIGATOR
Dr Vidya Navaratnam (Nedlands)
LOCATION
Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)
THIS CLINICAL TRIAL IS CURRENTLY CLOSED
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.